Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysis

Journal of Neural Transmission

Volumn 115, Issue 6, 2008, Pages 889-898

  Kamal, Mohammad A ^a   Qu, Xianqin ^a   Yu, Qian Sheng ^b   Tweedie, David ^b   Holloway, Harold W ^b   Li, Yazhou ^b   Tan, Yi ^a   Greig, Nigel H ^b  

^a UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^b NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Acetylcholinesterase; Alzheimer's disease; Anticholinesterase; Bisnorcymserine; Butyrylcholinestrase; Cymserine; Enzyme inhibition kinetics; Tetrahydrofurobenzofuran

Indexed keywords

CHOLINESTERASE; CHOLINESTERASE INHIBITOR; TETRAHYDROFUROBENZOFURAN CYMSERINE;

ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG HALF LIFE; ENZYME KINETICS; HUMAN; IC 50; PRIORITY JOURNAL; PROTEIN INTERACTION;

ALZHEIMER DISEASE; BINDING, COMPETITIVE; BUTYRYLCHOLINESTERASE; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; FURANS; HUMANS; KINETICS; MOLECULAR STRUCTURE; PHYSOSTIGMINE; SERUM;

EID: 44949096480     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-008-0022-y     Document Type: Article

References (52)

1. Arendt T, Bigl V, Walther F, Sonntag M (1984) Decreased ratio of CSF acetylcholinesterase to butyrylcholinesterase activity in Alzheimer's disease. Lancet 1:173
2. Arendt T, Bruckner MK, Lange M, Bigl V (1992) Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development-a study of molecular forms. Neurochem Int 21:381-396
3. Ballard CG, Greig NH, Guillozet-Bongaarts AL, Enz A, Darvesh S (2005) Cholinesterases: roles in the brain during health and disease. Curr Alzheimer Res 2:307-318
4. Bartels CF, Jensen FS, Lockridge O (1992) DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites. Am J Hum Genet 50:1086-1103
5. Bradford M (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254
6. Cerbai F, Giovannini MG, Melani C, Enz A, Pepeu G (2007) N1phenethyl-norcymserine, a selective butyrylcholinesterase inhibitor, increases acetylcholine release in rat cerebral cortex: a comparison with donepezil and rivastigmine. Eur J Pharmacol 572:142-150
7. Courtney C (2004) AD2000 collaborative group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 363(9427):2105-2115
8. Cummings JL (2004) Alzheimer's disease. N Engl J Med 351:56-67
9. Darvesh S, Hopkins DA (2003) Differential distribution of butyrylcholinesterase and acetylcholinesterase in the human thalamus. J Comp Neurol 463:25-43
10. Darvesh S, Grantham DL, Hopkins DA (1998) Butyrylcholinesterase in normal human amygdala and hippocampal formation. J Comp Neurol 393:374-390
11. Darvesh S, Hopkins DA, Geula C (2003) Neurobiology of butyrylcholinesterase. Nat Rev Neurosci 4:131-138
12. Déniz-Naranjo MC, Muñoz-Fernández C, Alemany-Rodríguez MJ, Pérez-Vieitez Mdel C, Aladro-Benito Y, Irurita-Latasa J, Sánchez-García F (2007) Butyrylcholinesterase, ApoE and Alzheimer's disease in a population from the Canary Islands (Spain). Neurosci Lett 427:34-38
13. Doraiswamy PM, Xiong GL (2006) Pharmacological strategies for the prevention of Alzheimer's disease. Expert Opin Pharmacother 7:1-10
14. Duysen EG, Li B, Darvesh S, Lockridge O (2007) Sensitivity of butyrylcholinesterase knockout mice to (-)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission. Toxicology 233:60-69
15. Ellman GL, Courtney KD, Andres V Jr, Featherstone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88-95
16. Farlow MR, Cummings JL (2007) Effective pharmacologic management of Alzheimer's disease. Am J Med 120:388-97
17. Giacobini E (2003) Butyrlcholinesterase: its function and inhibitors. Martin Dunitz, London and New York
18. Greig NH, Pei X-F, Soncrant T, Ingram DK, Brossi A (1995) Phenserine and ring-C hetero-analogues: drug candidates for the treatment of Alzheimer's disease. Med Chem Rev 15:3-31
19. Greig NH, Lahiri DK, Sambamurti K (2002) Butyrylcholinesterase: an important new target in Alzheimer's disease therapy. Int Psychogeriatr 14:77-91
20. Greig NH, Ruckle J, Comer P, Brownell L, Holloway HK, Flanagan DR Jr, Canfield CJ, Burford RG (2005a) Anticholinesterase and pharmacokinetic profile of phenserine in healthy elderly human subjects. Curr Alzheimer Res 2:483-492
21. Greig NH, Sambamurti K, Yu Q-S, Brossi A, Bruinsma G, Lahiri DK (2005b) An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Curr Alzheimer Res 2:281-291
22. Greig NH, Utsuki T, Ingram DK, Wang Y, Pepeu G, Scali C, Yu QS, Mamczarz J, Holloway HW, Giordano T, Chen D, Furukawa K Sambamurti K, Brossi A, Lahiri DK (2005c) Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent. Proc Natl Acad Sci USA 102:17213-17218
23. Guillozet AL, Smiley JF, Mash DC, Mesulam M (1997) Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol 42:909-18
24. Hardy J (2006) Has the amyloid cascade hypothesis for Alzheimer's disease been proved? Curr Alzheimer Res 3:71-73
25. Hartmann J, Kiewert C, Duysen EG, Lockridge O, Greig NH, Klein J (2007) Excessive levels of hippocampal acetylcholine in acetylcholinesterase-knockout mice are moderated by butyrylcholinesterase activity. J Neurochem 100:1421-1428
26. Holmes C, Ballard CG, Lehmann D, David Smith A, Beaumont H, Day IN, Nadeem Khan M, Lovestone S, McCulley M, Morris CM, Munzo DG, Russ C, Del Ser T, Warden D (2005) Rate of progression of cognitive decline in Alzheimer's disease: effect of butyrylcholinesterase K gene variation. J Neurol Neurosurg Psychiatry 76:640-643
27. Kamal MA, Al-Jafari AA, Yu Q-S, Greig NH (2006a) Kinetic analysis of the inhibition of human butyrylcholinesterase with cymserine. Biochim Biophys Acta 1760:200-206
28. Kamal MA, Yu Q-S, Holloway HW, Tweedie D, Klein P, Greig NH (2006b) Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine. J Alzheimers Dis 10:43-51
29. Kamal MA, Klein P, Yu Q-S, Holloway HW, Tweedie D, Greig NH (2007) Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine. Neurochem Res. doi: 10.1007/s11064-007-9490-y
30. Lacor PN (2004) Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci 24:10191-10200
31. Lahiri DK, Rogers JT, Greig NH, Sambamurti K (2004) Rationale for the development of cholinesterase inhibitors as anti-Alzheimer agents. Curr Pharm Des 10:3111-3119
32. Lahiri DK, Chen D, Maloney B, Holloway HW, Yu QS, Utsuki T, Giordano T, Sambamurti K, Greig NH (2007) The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice. J Pharmacol Exp Ther 320:386-396
33. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440:352-357
34. Lopez OL (2005) Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition. J Am Geriatr Soc 53:83-87
35. Luo W, Yu QS, Holloway HW, Greig NH, Brossi A (2005a) Syntheses of tetrahydrofurobenzofurans and dihydro-methanobenzodioxepines from 5-hydroxy-3-methyl-3H-benzofuran-2-one. Re-arrangement and ring expansion under reductive conditions on treatment with hydrides. J Org Chem 70:6171-6176
36. Luo X, Yu QS, Zhan M, Parrish D, Deschamps JR, Kulkarni SS, Holloway HW, Alley GM, Lahiri DK, Brossi A, Greig NH (2005b) Novel anticholinesterases based on the molecular skeletons of furobenzofuran and benzodioxepine. J Med Chem 48:986-994
37. Luo W, Yu QS, Kulkarni SS, Holloway HW, Parrish D, Tweedie D, Lahiri DK, Brossi A, Greig NH (2006) (-) And (+)-o-carbamoyl phenols of pyrroloindole, furoindole, furobenzofuran and benzodioxepine: enantiomeric syntheses and structure/activity relationship for human acetyl- and butyrylcholinesterase inhibitory action. J Med Chem 49:2174-2185
38. Mesulam M-M, Guillozet A, Shaw P, Levey A, Duysen EG, Lockridge O (2002) Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neuroscience 110:627-639
39. O'Brien KK, Saxby BK, Ballard CG, Grace J, Harrington F, Ford GA, O'Brien GT, Swan AG, Fairbairn AF, Wesnes W, Del Ser T, Edwardson JA, Morris CM, McKeith IG (2003) Regulation of attention and response to therapy in dementia by butyrylcholinesterase. Pharmacogenetics 13:231-239
40. Perry EK (1986) The cholinergic hypothesis-ten years on. Br Med Bull 42:63-69
41. Perry EK, Perry RH, Blessed G, Tomlinson BE (1978) Changes in brain cholinesterase in senile dementia of Alzheimer's type. Neuropathol Appl Neurobiol 4:273-277
42. Rice SG, Nowak L, Duysen EG, Lockridge O, Lahiri DK, Reyes PF (2007) Neuropathological and immunochemical studies of brain parenchyma in acetylcholinesterase knockout mice: implications in Alzheimer's disease. J Alzheimers Dis 11:481-489
43. Sambamurti K, Greig NH, Lahiri DK (2002) Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease. Neuromolecular Med 1:1-31
44. Sambamurti K, Anitha S, Venugopal C, Prakasam A, Zhou Y, Lahiri DK, Greig NH (2006) A partial failure of membrane protein turnover may cause Alzheimer's disease: a new hypothesis. Curr Alzheimer Res 3:81-90
45. Selkoe DJ (2005) Defining molecular targets to prevent Alzheimer disease. Arch Neurol 62:192-195
46. Silver A (1974) The biology of cholinesterases. Elsevier, Amsterdam
47. Sisodia SS, St George-Hyslop PH (2002) gGamma-secretase, notch, Abeta and Alzheimer's disease: where do the presenilins fit in? Nat Rev Neurosci 3:281-290
48. Small DH (2005) Acetylcholinesterase inhibitors for the treatment of dementia in Alzheimer's disease: do we need new inhibitors? Expert Opin Emerg Drugs 10:817-825
49. Soreq H, Zakut H (1993) Human cholinesterases and anticholinesterases. Academic, New York
50. Souza RL, Mikami LR, Maegawa RO, Chautard-Freire-Maia EI (2005) Four new mutations in the BCHE gene of human butyrylcholinesterase in a Brazilian blood donor sample. Mol Genet Metab 84:349-353
51. Standridge JB (2004) Pharmacotherapeutic approaches to the treatment of Alzheimer's disease. Clin Ther 26:615-630
52. Yu QS, Holloway HW, Utsuki T, Brossi A, Greig NH (1999) Phenserine-based synthesis of novel selective inhibitors of butyrylcholinesterase for Alzheimer's disease. J Med Chem 42:1855-1861